Zanamivir: Difference between revisions
imported>David E. Volk m (→External links) |
mNo edit summary |
||
| (2 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
{{subpages}} | {{subpages}} | ||
[[Image:Zanamivir structure.jpg| | |||
{{Chem infobox | |||
|align=right | |||
|image=[[Image:Zanamivir structure.jpg|center|thumb|250px]] | |||
|width=250px | |||
|molname=zanamivir | |||
|synonyms= Relenza® | |||
|molformula= C<sub>12</sub>H<sub>20</sub>N<sub>4</sub>O<sub>7</sub> | |||
|molmass=332.3098 | |||
|uses=influenza A & B | |||
|properties=neuraminidase inhibitor | |||
|hazards=see drug interactions | |||
|iupac= see chemistry section | |||
|casnumber=139110-80-8 | |||
}} | |||
'''Zanamivir''' is a guanido-neuraminic acid that is a [[neuraminidase]] inhibitor used as an [[antiviral drug]] to treat [[influenza]] A and B. | '''Zanamivir''' is a guanido-neuraminic acid that is a [[neuraminidase]] inhibitor used as an [[antiviral drug]] to treat [[influenza]] A and B. | ||
Its IUPAC chemical name is (4S,5R,6R)-5-acetamido-4-(diaminomethylideneamino)-6-[(1R,2R)-1,2,3-trihydroxypropyl]-5,6-dihydro-4H-pyran-2-carboxylic acid and its chemical formula is C<sub>12</sub>H<sub>20</sub>N<sub>4</sub>O<sub>7</sub>. | Its IUPAC chemical name is (4S,5R,6R)-5-acetamido-4-(diaminomethylideneamino)-6-[(1R,2R)-1,2,3-trihydroxypropyl]-5,6-dihydro-4H-pyran-2-carboxylic acid and its chemical formula is C<sub>12</sub>H<sub>20</sub>N<sub>4</sub>O<sub>7</sub>. | ||
==Dosage== | |||
According to MedMaster, "the recommended dose of RELENZA for ''treatment'' of influenza in adults and pediatric patients ages 7 years of age and older is 10 mg twice daily (approximately 12 hours apart) for 5 days." Zanamivir is administered by inhalation and is supplied at 5 mg blister per dose so 20 blisters are needed. One Relenza Diskhaler contains 20 blisters. | |||
== Brand names == | == Brand names == | ||
| Line 14: | Line 31: | ||
== External links == | == External links == | ||
{{CZMed}} | |||
[[Category:Suggestion Bot Tag]] | |||
Latest revision as of 07:01, 10 November 2024
|
| |||||||
| zanamivir | |||||||
| |||||||
| Uses: | influenza A & B | ||||||
| Properties: | neuraminidase inhibitor | ||||||
| Hazards: | see drug interactions | ||||||
| |||||||
Zanamivir is a guanido-neuraminic acid that is a neuraminidase inhibitor used as an antiviral drug to treat influenza A and B.
Its IUPAC chemical name is (4S,5R,6R)-5-acetamido-4-(diaminomethylideneamino)-6-[(1R,2R)-1,2,3-trihydroxypropyl]-5,6-dihydro-4H-pyran-2-carboxylic acid and its chemical formula is C12H20N4O7.
Dosage
According to MedMaster, "the recommended dose of RELENZA for treatment of influenza in adults and pediatric patients ages 7 years of age and older is 10 mg twice daily (approximately 12 hours apart) for 5 days." Zanamivir is administered by inhalation and is supplied at 5 mg blister per dose so 20 blisters are needed. One Relenza Diskhaler contains 20 blisters.
Brand names
- GANA
- GNA
- Relenza (GlaxoSmithKline)
- ZMR
- Zanamavir
External links
The most up-to-date information about Zanamivir and other drugs can be found at the following sites.
- Zanamivir - FDA approved drug information (drug label) from DailyMed (U.S. National Library of Medicine).
- Zanamivir - Drug information for consumers from MedlinePlus (U.S. National Library of Medicine).
- Zanamivir - Detailed information from DrugBank.